Nabla Bio

📍 Cambridge, United States👥 22 employees💰 Last funded Jan 2024
Biotechnology🌐 nabla.bio
Website LinkedIn
We develop AI and wet-lab technologies that enable the rational design of developable, selective, and functional drugs against previously undruggable targets. To maximize the patient impact of our platform, we collaborate with leading pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb and Takeda, to expand their pipelines with high-quality drug candidates. If successful we could double the number of disease-relevant drug targets the industry advances for drug development. Since launching in 2021 we have raised $37 million with the backing of leading investors, including Radical Ventures, Khosla Ventures and Zetta Venture Partners. Our technical team is based in Cambridge, Massachusetts and continues to recruit top machine learning and synthetic biology talent. For more information check out the Careers section of our website at www.nabla.bio.
4
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
3
Canada
1
Investor activity2021–2024 · investors recorded per year
2021220242
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Nabla Bio?
Nabla Bio has 4 investors on record on gritt.io.
When did Nabla Bio last raise funding?
The most recent investment in Nabla Bio recorded on gritt.io was in January 2024.
What industry is Nabla Bio in?
Nabla Bio operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Nabla Bio based?
Nabla Bio is headquartered in Cambridge, United States.